Inozyme Pharma Inc (OQ:INZY)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 321 SUMMER STREET, SUITE 400
BOSTON MA 02210
Tel: N/A
Website: www.inozyme.com
IR: See website
<
Key People
Axel Bolte
Chief Executive Officer, Co-Founder
Henric Bjorn Bjarke
Chief Operating Officer, Senior Vice President
David Thompson
Senior Vice President, Chief Scientific Officer
Steven J Jungles
Senior Vice President , Chief Technical Operations Officer
Stephen Basso
Vice President - Finance
 
Business Overview
Inozyme Pharma, Inc. is a rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
Financial Overview
For the three months ended 31 March 2020, Inozyme Pharma Inc revenues was not reported. Net loss increased 56% to $7.7M. Higher net loss reflects Research and development - Balancing va increase of 54% to $6.3M (expense), General and administrative - Balancing increase of 41% to $1.4M (expense), Stock-based Compensation in SGA increase from $14K to $64K (expense).
Employees: 24 as of Jun 5, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $537.16M as of Mar 31, 2020
Annual revenue (TTM): $0.00M as of Mar 31, 2020
EBITDA (TTM): -$23.46M as of Mar 31, 2020
Net annual income (TTM): -$22.49M as of Mar 31, 2020
Free cash flow (TTM): -$19.98M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 22,314,851 as of Jul 24, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.